NPS Pharmaceuticals' Gattex Gets Updated Label - Analyst Blog

By
A A A

NPS Pharmaceuticals ( NPSP ) announced that the label of its sole marketed product, Gattex, has been updated by the FDA. The U.S. label of the drug now includes long-term data from STEPS 2 (n=88) - the two-year open-label extension of the 24-week phase III international STEPS study.

Gattex is available in the U.S. since Feb 2013 for treating adults with short bowel syndrome, dependent on parenteral support. The STEPS 2 study proved the effectiveness of Gattex for long-term use.  

Data from the study revealed additional and clinically meaningful reductions in the volume and days/week of parenteral support requirements in patients who continued treatment with the drug beyond two years. In addition, data from the extension study showed that 13 patients achieved complete independence from parenteral support. Moreover, long-term Gattex treatment did not result in any new unexpected safety issues.

We remind investors that the FDA accepted NPS Pharma's marketing application seeking to update Gattex's label in Nov 2013. The favorable FDA decision should augment the drug's sales potential.

NPS Pharma expects to add another product - Natpara (rhPTH [1-84]) - to its portfolio later in the year. The company is looking to get Natpara, which has been granted orphan drug status in the U.S. and EU, approved for treating hypoparathyroidism. The candidate is currently under review in the U.S. A decision from the FDA on Natpara is expected by Oct 24, 2014. Approval of Natpara would reduce the company's dependence on Gattex for growth.

NPS Pharma carries a Zacks Rank #5 (Strong Sell). Better-ranked stocks in the healthcare sector include Regeneron Pharmaceuticals ( REGN ), Biogen Idec ( BIIB ) and The Medicines Company ( MDCO ). All three stocks sport a Zacks Rank #1 (Strong Buy).


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

REGENERON PHARM (REGN): Free Stock Analysis Report

MEDICINES CO (MDCO): Free Stock Analysis Report

BIOGEN IDEC INC (BIIB): Free Stock Analysis Report

NPS PHARMA INC (NPSP): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: REGN , MDCO , BIIB , NPSP

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

29,814,250
  • $15.525 ▲ 0.03%
23,491,480
  • $69.3934 ▼ 0.01%
22,135,950
  • $94.232 ▲ 0.31%
20,359,904
  • $3.82 ▲ 1.06%
19,422,988
  • $34.491 ▲ 1.27%
18,489,907
  • $44.971 ▲ 0.30%
18,376,593
  • $2.51 ▲ 13.57%
16,473,821
  • $25.8885 ▼ 0.35%
As of 7/22/2014, 12:13 PM